KRRO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Korro Bio Inc (KRRO) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong analyst upgrades, hedge fund buying activity, and a promising pipeline with KRRO-121. Despite weak financials, the potential for significant upside and the lack of negative news make it a compelling opportunity.
The MACD is slightly positive and contracting, indicating a neutral to slightly bullish trend. RSI is neutral at 44.622, and moving averages are converging, suggesting no strong directional bias. The stock is trading near support levels (S1: 11.203), which could provide a good entry point.
Multiple analyst upgrades with significantly increased price targets (up to $30). Hedge fund buying activity has surged by 1445.31% in the last quarter. KRRO-121's promising preclinical data and potential regulatory path provide a strong growth narrative.
Weak financial performance in Q3 2025, with net income and EPS declining significantly YoY. No recent news or congress trading data to further validate sentiment.
In Q3 2025, revenue remained flat at $1.09M YoY. However, net income dropped to -$18.06M (-13.99% YoY), and EPS fell to -1.92 (-15.04% YoY). Despite a 100% gross margin, the company is not yet profitable.
Analysts are overwhelmingly bullish on KRRO, with multiple upgrades to Buy or Overweight and price targets ranging from $15 to $30. Analysts highlight KRRO-121's strong preclinical data and its potential to address high unmet medical needs, providing a fresh growth story for the company.
